Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders

被引:6
|
作者
Vassilopoulou, Emilia [1 ]
Efthymiou, Dimitris [2 ]
Papatriantafyllou, Evangelia [1 ]
Markopoulou, Maria [3 ]
Sakellariou, Efthymia-Maria [4 ]
Popescu, Alina Codruta [5 ]
机构
[1] Int Hellen Univ, Dept Nutr Sci & Dietet, Thessaloniki 57400, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Div Neurosci, Dept Psychiat, Thessaloniki 54124, Greece
[3] Psychiat Hosp Thessaloniki, Dept Forens Psychiat, Thessaloniki 56429, Greece
[4] Gen Univ Hosp, Psychiat Clin, Larisa 41110, Greece
[5] Iuliu Hatieganu Univ Med & Pharm, Dept Abil Human Sci, Cluj Napoca 400012, Romania
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 11期
关键词
forensic psychiatry; antipsychotic drugs; metabolic disturbances; WEIGHT-GAIN; CARDIOMETABOLIC RISK; 1ST-EPISODE SCHIZOPHRENIA; DRUGS; ANTIDEPRESSANTS; ZIPRASIDONE; OLANZAPINE; QUETIAPINE; CLOZAPINE; LEPTIN;
D O I
10.3390/jpm11111189
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Mentally disordered offenders provided with forensic psychiatric care are often treated with second generation antipsychotic (SGA) medication and experience metabolic and inflammatory side effects. Aim: In this paper, we monitored the three-year fluctuation of selected anthropometric, biochemical, and inflammatory indices in forensic psychiatric patients receiving antipsychotic (AP) medication for more than five years, according to the type of AP. Methods: Thirty-five patients with psychotic disorders were classified into two groups based on the type of AP. Specifically: AP1, related to a lower risk, and AP2, related to an increased risk of weight gain (WG) and metabolic complications. Biochemical, hematological, anthropometric, blood pressure (BP), and medication data were retrieved from the individual medical files. Statistical analysis was performed with SPSS 23. Results: No significant differences in weight and glucose and cholesterol levels were observed, but patients taking AP2 more often needed drugs to control diabetes mellitus (DM), lipidemia, and cardiovascular disease (CVD). In those taking AP1, the mean HDL level decreased significantly over time (p < 0.05) and a higher proportion developed higher BP (52.9% of AP1 vs. 16.7% AP2). In the AP2 group the median level of C-reactive protein (CRP) (p < 0.001) and the white blood cell count (WBC) increased over the three years (p < 0.001). Conclusions: The proposed sub-classification of SGAs into AP1 and AP2, depending on their potential for metabolic and inflammatory effects, might facilitate study of their long-term side-effects but also help in personalized prevention or treatment measures to counteract these side-effects.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?
    Van Schependom, Jeroen
    Yu, Weiping
    Gielen, Jeroen
    Laton, Jorne
    De Keyser, Jacques
    De Hert, Marc
    Nagels, Guy
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (10) : E1292 - E1299
  • [42] Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers
    Miller, Brian J.
    McCall, William, V
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2022, 18 (02): : 517 - 522
  • [43] The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk
    Ferrara, Maria
    Umlauf, Anya
    Sanders, Chelsea
    Meyer, Jonathan M.
    McCutchan, John Allen
    Duarte, Nichole
    Atkinson, Joseph Hampton
    Grant, Igor
    Ellis, Ronald J.
    PSYCHIATRY RESEARCH, 2014, 218 (1-2) : 201 - 208
  • [44] Incidence of Oculogyric Crisis and Long-Term Outcomes With Second-Generation Antipsychotics in a First-Episode Psychosis Program
    Gardner, David M.
    Abidi, Sabina
    Ursuliak, Zenovia
    Morrison, Jason
    Teehan, Michael D.
    Tibbo, Philip G.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (06) : 715 - 718
  • [45] Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
    De Hert, M.
    Dobbelaere, M.
    Sheridan, E. M.
    Cohen, D.
    Correll, C. U.
    EUROPEAN PSYCHIATRY, 2011, 26 (03) : 144 - 158
  • [46] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
    Lik Hang N. Lee
    Charles Choi
    Abby C. Collier
    Alasdair M. Barr
    William G. Honer
    Ric M. Procyshyn
    CNS Drugs, 2015, 29 : 975 - 983
  • [47] Easy and Low-Cost Identification of Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics: Artificial Neural Network and Logistic Regression Models
    Lin, Chao-Cheng
    Bai, Ya-Mei
    Chen, Jen-Yeu
    Hwang, Tzung-Jeng
    Chen, Tzu-Ting
    Chiu, Hung-Wen
    Li, Yu-Chuan
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (03) : 225 - 234
  • [48] A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
    Boyda, Heidi N.
    Procyshyn, Ric M.
    Tse, Lurdes
    Yuen, Jessica W. Y.
    Honer, William G.
    Barr, Alasdair M.
    PLOS ONE, 2021, 16 (01):
  • [49] Haloperidol Versus Second-Generation Antipsychotics in the Long-Term Treatment of Schizophrenia A 4-Year Follow-Up Naturalistic Study
    Altamura, Alfredo Carlo
    Buoli, Massimiliano
    Mauri, Massimo Carlo
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (05) : 661 - 663
  • [50] Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia A Naturalistic, Comparative Study
    Chan, Hung-Yu
    Pan, Yi-Ju
    Chen, Jiahn-Jyh
    Chen, Chiung-Hsu
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (01) : 13 - 20